Targeting DNA methylation

Mar 04, 2021

Sequence from project that provides insight on the role aberrant DNA methylation has in the abnormalities responsible for cancer cell growth, especially hematological malignancies such as leukemia, lymphoma, and multiple myeloma.

In this sequence, we begin with a view of “normal” DNA methylation, and then change to a view of hypermethylation underway.

Eventually, decitabine – a hypomethylating agent – can be seen moving into place and blocking DNA methyltransferase (DNMT), leading to the degradation of DNMT and eventual hypomethylation.

Targeting DNA methylation with DNA hypomethylating agents (HMAs) acts to reprogram tumor cells to a more normal-like state.

View animation >>

Tagged: , , , , , , , , , , , , , , , , , , , , , , , , , , ,


sleep animation

The healing power of sleep

May 17, 2021

Sequence from immersive 1.5-minute 360° animation where we explore the benefits of sleep.

Here within the neural microspace of the brain, we depict the “cleansing system” of the brain: the glymphatic system. 

Just like the rest of your body, the brain accumulates waste. Recent discoveries have shown that cerebral spinal fluid “flushes” debris and metabolic toxins out of the neural microspace during the deep sleep phase. 

We also watch the heart beating (and lungs breathing) inside the chest cavity and discuss the role of sleep in reducing your risk for cardiovascular diseases.

View animation >>

Tagged: , , , , , , , , , , , , , , , , , , , , , , ,


The endocannabinoid system (ECS)

Jan 15, 2021

1.5-minute animation created for CME event. 

Our assignment included the development of the science story and creation of key events that would inform and educate viewers on the physiologic functions associated with the endocannabinoid system (ECS), the role of CB1 retrograde signaling, as well as the enzymes involved in the degradation of endocannabinoids.

We had the pleasure and honor of collaborating closely with the speaker of this event; she is also noted for her discovery of the CB1 receptor for cannabinoid agonists.

The target audience included neurologists, primary care physicians, and pediatricians.

View animation >>

Tagged: , , , , , , , , , , , , , , , , , , , , ,